文献速递消化、代谢与肾脏急症儿科与产科急症

重症肌无力患者的COVID-19感染与疫苗接种结局

Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论基于人群的匹配队列研究提示,重症肌无力患者感染COVID-19后住院和死亡风险高于匹配对照,而疫苗接种率高且严重病情加重风险极低。

该基于加拿大安大略省行政健康数据的匹配队列研究纳入4411例重症肌无力患者,按年龄、性别和居住地匹配22255名一般人群对照和22255名类风湿关节炎对照。2020年1月15日至2021年5月17日,重症肌无力患者COVID-19感染率为3.7%,高于一般人群对照的3.0%和类风湿关节炎对照的3.0%;感染后急诊就诊率、住院率和30天死亡率均更高。截至2021年8月,重症肌无力患者两剂疫苗接种率为80.3%,与一般人群对照的81.2%相近;接种首剂后30天内因病情加重住院者少于6例;接种疫苗的重症肌无力患者感染COVID-19的风险低于未接种者(HR 0.43,95%CI 0.30-0.60)。作者认为研究结果支持将重症肌无力患者列为疫苗接种和新型COVID-19治疗优先人群的公共卫生政策。

要点

  • 重症肌无力患者感染COVID-19后住院率30.5%(50/164),高于一般人群对照的15.1%(101/669)和类风湿关节炎对照的20.7%(138/668)。
  • 重症肌无力患者感染COVID-19后30天死亡率14.6%(24/164),高于一般人群对照的8.5%(57/669)和类风湿关节炎对照的9.9%(66/668)。
  • 截至2021年8月,重症肌无力患者两剂疫苗接种率80.3%(3540例),一般人群对照81.2%(17913例);一剂接种率分别为3.1%(137例)和2.8%(628例)。
  • 3461例重症肌无力患者接种首剂疫苗后30天内,因病情加重住院者少于6例。
  • 接种疫苗的重症肌无力患者感染COVID-19风险低于未接种者(HR 0.43,95%CI 0.30-0.60)。

适用人群与场景

  • 加拿大安大略省成年重症肌无力患者,采用经验证的算法识别,按年龄、性别和居住地以1:5匹配一般人群对照和类风湿关节炎对照。
  • 数据来源为2020年1月15日至2021年8月31日的行政健康数据。

研究设计与关键结果

  • 研究类型为基于人群的匹配队列研究,纳入4411例重症肌无力患者(平均[SD]年龄67.7[15.6]岁;女性2274例[51.6%]),匹配22255名一般人群对照(平均[SD]年龄67.7[15.6]岁;女性11370例[51.6%])和22255名类风湿关节炎对照(平均[SD]年龄67.7[15.6]岁;女性11370例[51.6%])。
  • 匹配队列中38861/44110例(88.1%)为城市居民;重症肌无力队列中3901例(88.4%)为城市居民。
  • 2020年1月15日至2021年5月17日,重症肌无力患者COVID-19感染164例(3.7%),一般人群对照669例(3.0%),类风湿关节炎对照668例(3.0%)。
  • 感染COVID-19后急诊就诊率:重症肌无力患者36.6%(60/164),一般人群对照24.4%(163/669),类风湿关节炎对照29.9%(200/668)。
  • 感染COVID-19后住院率:重症肌无力患者30.5%(50/164),一般人群对照15.1%(101/669),类风湿关节炎对照20.7%(138/668)。
  • 感染COVID-19后30天死亡率:重症肌无力患者14.6%(24/164),一般人群对照8.5%(57/669),类风湿关节炎对照9.9%(66/668)。
  • 截至2021年8月,重症肌无力患者两剂疫苗接种3540例(80.3%),一般人群对照17913例(81.2%);一剂接种分别为137例(3.1%)和628例(2.8%)。
  • 3461例重症肌无力患者接种首剂疫苗后30天内,因病情加重住院者少于6例;接种疫苗的重症肌无力患者感染COVID-19风险低于未接种者(HR 0.43,95%CI 0.30-0.60)。

证据类型、等级与局限

  • 证据类型为基于人群的匹配队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果支持公共卫生政策将重症肌无力患者列为疫苗接种和新型COVID-19治疗的优先人群。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There are limited data regarding COVID-19 outcomes and vaccine uptake and safety among people with myasthenia gravis (MG).

OBJECTIVE: To investigate COVID-19-related outcomes and vaccine uptake among a population-based sample of adults with MG.

DESIGN, SETTING, AND PARTICIPANTS: This population-based, matched cohort study in Ontario, Canada, used administrative health data from January 15, 2020, and August 31, 2021. Adults with MG were identified using a validated algorithm. Each patient was matched by age, sex, and geographic area of residence to 5 controls from the general population and from a cohort of individuals with rheumatoid arthritis (RA).

EXPOSURE: Patients with MG and matched controls.

MAIN OUTCOMES AND MEASURES: Main outcomes were COVID-19 infection and related hospitalizations, intensive care unit admissions, and 30-day mortality among patients with MG vs controls. Secondary outcomes were uptake of COVID-19 vaccination among patients with MG vs controls.

RESULTS: Among 11 365 233 eligible Ontario residents, 4411 patients with MG (mean [SD] age, 67.7 [15.6] years; 2274 women [51.6%]) were matched to 22 055 general population controls (mean [SD] age, 67.7 [15.6] years; 11 370 women [51.6%]) and 22 055 controls with RA (mean [SD] age, 67.7 [15.6] years; 11 370 women [51.6%]). In the matched cohort, 38 861 of 44 110 individuals (88.1%) were urban residents; in the MG cohort, 3901 (88.4%) were urban residents. Between January 15, 2020, and May 17, 2021, 164 patients with MG (3.7%), 669 general population controls (3.0%), and 668 controls with RA (3.0%) contracted COVID-19. Compared with general population controls and controls with RA, patients with MG had higher rates of COVID-19-associated emergency department visits (36.6% [60 of 164] vs 24.4% [163 of 669] vs 29.9% [200 of 668]), hospital admissions (30.5% [50 of 164] vs 15.1% [101 of 669] vs 20.7% [138 of 668]), and 30-day mortality (14.6% [24 of 164] vs 8.5% [57 of 669] vs 9.9% [66 of 668]). By August 2021, 3540 patients with MG (80.3%) vs 17 913 general population controls (81.2%) had received 2 COVID-19 vaccine doses, and 137 (3.1%) vs 628 (2.8%), respectively had received 1 dose. Of 3461 first vaccine doses for patients with MG, fewer than 6 individuals were hospitalized for MG worsening within 30 days of vaccination. Vaccinated patients with MG had a lower risk than unvaccinated patients with MG of contracting COVID-19 (hazard ratio, 0.43; 95% CI, 0.30-0.60).

CONCLUSIONS AND RELEVANCE: This study suggests that adults with MG who contracted COVID-19 had a higher risk of hospitalization and death compared with matched controls. Vaccine uptake was high, with negligible risk of severe MG exacerbations after vaccination, as well as evidence of effectiveness. The findings support public health policies prioritizing people with MG for vaccination and new COVID-19 therapeutics.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Alcantara M, Koh M, Park AL, et al. Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis. JAMA Netw Open. 2023. PMID: 37097637. doi:10.1001/jamanetworkopen.2023.9834

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。